« Back
Home /
Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-B9) - HRP - 50 µg

Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-B9) - HRP - 50 µg

Item no.	LEIN-LT7082-50ug
Manufacturer	Leinco Technologies
Amount	50 ug
Category	Antibodies ELISA Primary Antibodies Immunostaining
Type	Antibody Monoclonal
Applications	ELISA
Clone	NP1-B9
Specific against	Virus, SARS-CoV-2
Host	Mouse
NCBI	43740575
ECLASS 10.1	42030590
ECLASS 11.0	42030590
UNSPSC	12352203
Shipping Condition	Cool pack
Available
Manufacturer - Applications	Quality Tested by Leinco ELISA
Manufacturer - Category	Primary Monoclonal Antibodies>Infectious Diseases\|Monoclonal Antibodies\|Recombinant Antibodies\|SARS-CoV-2
Manufacturer - Targets	SARS-CoV-2 Nucleocapsid (N)
Country of Origin	USA
Shipping Temperature	Ships Overnight on Blue Ice
Storage Conditions	This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.
Product Description	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family1. The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. SARS-CoV-2 shares 79.6% identity with the original SARS-CoV2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization3, 4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6, 7. The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein9. Furthermore, antibodies9, 10 and memory T cells11, 12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic.
Background	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family¹. The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins². SARS-CoV-2 shares 79.6% identity with the original SARS-CoV². The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization^{3, 4}. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein⁵. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways^{6, 7}. The N protein is a suitable candidate for vaccine development and diagnostic assays⁸ for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein⁹. Furthermore, antibodies^{9, 10} and memory T cells^{11, 12} targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system¹³, suggesting its potential value as a targeted therapeutic.
PubMed	SARS-CoV-2 Nucleocapsid (N)
Manufacturer - Research Area	COVID-19, Infectious Disease, Seasonal and Respiratory Infections, Viral, IVD Raw Material
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	Anti-SARS-CoV-2 Nucleocapsid, clone NP1-B9, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein.
RRID	AB_2894012
Concentration	0.5 mg/ml
Formulation	This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
Antigen Distribution	The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.
Immunogen	SARS-CoV-2 Nucleocapsid (N) Protein
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein, Monoclonal Antibody, COVID-19

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-LT7082-50ug-safety-datasheet.pdf